🇺🇸 FDA
Pipeline program

L. helveticus R0052 and B. longum R0175

APB-C1

Approved other active

Quick answer

L. helveticus R0052 and B. longum R0175 for Attention Deficit Hyperactivity Disorder is a Approved program (other) at ACADIA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
ACADIA PHARMACEUTICALS INC
Indication
Attention Deficit Hyperactivity Disorder
Phase
Approved
Modality
other
Status
active

Clinical trials